The important role of secondary treatment in Hodgkin Lymphoma

ONCOLOGY (United States)

Volumn 26, Issue 12, 2012, Pages

  Connors, Joseph M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG TREATMENT FAILURE; EARLY STAGE HODGKIN LYMPHOMA; HODGKIN DISEASE; HUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SECONDARY PREVENTION;

EID: 84874594389     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkins lymphoma. N Engl J Med. 2012;366:399-408.
2. Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkins lymphoma--a report from the Childrens Oncology Group. J Clin Oncol. 2012;30:3174-80.
3. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkins disease. J Natl Cancer Inst. 1988;80:1466-73.
4. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkins lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721-7.
5. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkins lymphoma (HL). J Clin Oncol. 2005;23(16s): abstr 6505.
6. Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkins disease with bulky disease. Clin Lab Haematol. 1998;20:95-9.
7. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkins disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22:62-8.
8. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-9.
9. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkins lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812-26.
10. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkins lymphoma. J Clin Oncol. 2012;30:2183-9.